Fidelity Investments’s Oncolytics Biotech ONCY Stock Holding History

Fidelity Investments’s Portfolio ONCY Stock Details ONCY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1	Closed	–	–	4828
2021 Q2	$0	Buy	+1	New	+$3	﹤0.01%	4693

Other funds holding ONCY

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

IAIM

International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CIBC World Market Toronto, Ontario, Canada $61.3B AUM 39.33% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments's ONCY Position: Q3 2021 in Review

Fidelity Investments sold out of Oncolytics Biotech (ONCY) in Q3 2021, closing a stake of 1 share.

Fidelity Investments first reported a position in ONCY in Q2 2021 and held it in 1 quarter. The position peaked at $0 in Q2 2021. 37 funds tracked by Wall St. Rank hold ONCY as of Q3 2021.

Fidelity Investments reported no remaining Oncolytics Biotech position as of Q3 2021 after selling out during the quarter.
Fidelity Investments sold 1 Oncolytics Biotech share in Q3 2021.
Fidelity Investments first reported a position in Oncolytics Biotech in Q2 2021 and held it in 1 quarter.
Fidelity Investments's Oncolytics Biotech position peaked at $0 in Q2 2021.
37 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q3 2021.

Based on Fidelity Investments's 13F filing for Q3 2021, filed 15 Nov 2021.